Takeda Closes Acquisition Of Shire
Takeda Pharmaceutical Company Limited (TAK) said Monday that it completed acquisition of Shire plc.
The combined annual revenue of the company, exceeding $30 billion, is mainly derived from the key business areas of Oncology, GI, Neuroscience, Rare Diseases and PDT.
“We are delighted that the acquisition was approved by an overwhelming majority of our shareholders at Takeda’s extraordinary general meeting on December 5th, 2018. We are also pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organizations and the smooth receipt of regulatory clearances,” said Christophe Weber, President and Chief Executive Officer of Takeda.
Source: Read Full Article